

Curriculum vitae

Thorsten Stiewe Professor, Dr. med.
d.o.b. November 15th, 1970, in Gelsenkirchen, Germany

University Education

2006 Habilitation, Biochemistry and Molecular Biology, University of Würzburg
2004 Approbation
2000 Dr. med., University of Essen
1997 State examination in Medicine, University of Essen
1989 – 1997 University studies in Medicine and Chemistry, University of Essen

Scientific Career

Since 2022 Adjunct Faculty Member of the Institute of Lung Health, Giessen
2021 – 2025 Vice-Speaker, LOEWE network "iCANx: Cancer–Lung (Disease) Crosstalk: Tumor and Organ Microenvironment"
Since 2020 Speaker, Medical Core Facility Network, UMR
Since 2020 Member, Central Tenure Track Committee, UMR
Since 2015 Founding Director, Institute of Molecular Oncology, UMR
2014 – 2019 Member, Philipps-University Graduation Award Committee
Since 2011 Member, German Center for Lung Research (DZL)
2010 – 2022 Member, DFG Transregio TR81 "Chromatin changes in differentiation and malignancies"
Since 2010 Head of Genomics Core Facility, UMR
Since 2010 Professor (W3) for Molecular Oncology, UMR
2008 – 2013 Coordinator, DFG Integrated Graduate School "Molecular Cancer Biology" (SFB/Transregio TR17)
2007 – 2010 Professor (W2) for Molecular Oncology, Department of Hematology, Oncology and Immunology, Philipps University Marburg (UMR)
2004 – 2013 Executive board member, DFG Transregio TR17 "Ras-dependent pathways in human cancer"
2002 – 2007 Junior Group Leader, Rudolf-Virchow-Center (DFG Research Center for Experimental Biomedicine), University of Würzburg
2000 – 2002 Postdoctoral fellow, Institute of Molecular Biology, West German Cancer Center, University of Essen
1997 – 2000 Graduate student, Institute of Molecular Biology, West German Cancer Center, University of Essen

Awards and Honors

2014 Award for Research on Animal Welfare of the Federal State of Hesse
2010 European Research Council (ERC) Starting Grant
2007 C.G. Schmidt Medal for Cancer Research
2002 Wissenschaftspreis Medizin, University Essen
2002 Junior Group Award by the DFG Research Center Würzburg
2001 Forschungspreis Westdeutsches Tumorzentrum e.V.

Citation Record

Total citations: 10,195; h-index: 55; h-index since 2021: 41 (Google Scholar March 18, 2026)

Top-10 selected Publications

Merle N, Bullwinkel I, Timofeev O, Elmshäuser S, **Stiewe T** (2026). Secreted luciferases as a minimally invasive 3R-compliant tool for accurate monitoring of tumor burden. **Nat Protoc**, 2026. doi: 10.1038/s41596-025-01315-9 (IF 16.0)

Gremke N, Besong I, Stroh A, von Wichert L, Witt M, Elmshäuser S, Wanzel M, Fromm MF, Taudte RV, Schmatloch S, Karn T, Reinisch M, Hirmas N, Loibl S, Wündisch T, Litmeyer AS, Jank P, Denkert C, Griewing S, Wagner U, **Stiewe T** (2025). Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs. **Signal Transduct Target Ther** 10(1): 92. doi: 10.1038/s41392-025-02180-4 (IF 52.7)

Funk JS, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A, Noeparast M, Pavlakis E, Neumann M, Balourdas DI, Kochhan K, Merle N, Bullwinkel I, Wanzel M, Elmshäuser S, Teply-Szymanski J, Nist A, Procida T, Bartkuhn M, Humpert K, Mernberger M, Savai R, Soussi T, Joerger AC, **Stiewe T** (2025). Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. **Nat Genet** 2025; 57(1): 140-153. doi: 10.1038/s41588-024-02039-4 (IF 29.0)

Merle N, Elmshäuser S, Strassheimer F, Wanzel M, König AM, Funk J, Neumann M, Kochhan K, Helmprobst F, Pagenstecher A, Nist A, Mernberger M, Schneider A, Braun T, Borggreffe T, Savai R, Timofeev O, **Stiewe T** (2022). Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase. **Mol Cancer** 21(1): 191. doi: 10.1186/s12943-022-01661-2 (IF 41.44)

Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, **Stiewe T**, Pikarsky E, Oren M, and Ben-Neriah Y (2020). The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. **Nature** 586, 133-138. doi: 10.1038/s41586-020-2541-0 (IF 49.9)

Wanzel M, Vishedyk JB, Gittler MP, Gremke N, Seiz JR, Hefter M, Noack M, Savai R, Mernberger M, Charles JP, Schneikert J, Bretz AC, Nist A, **Stiewe T** (2016). CRISPR-Cas9-based target validation for p53-reactivating model compounds. **Nat Chem Biol** 12, 22–28. doi: 10.1038/nchembio.1965 (IF 16.29)

Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, Samans B, Eilers M, Kisker C, Rosenwald A, **Stiewe T** (2010). DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. **Mol Cell** 38, 356-68. doi: 10.1016/j.molcel.2010.02.037 (IF 19.34)

Stiewe T (2007). The p53 family in differentiation and tumorigenesis. **Nat Rev Cancer** 7, 165-8. doi: 10.1038/nrc2072 (IF 69.80)

Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Huttinger-Kirchhof N, Oswald C, Friedl P, Gattenlohner S, Burek C, Rosenwald A, **Stiewe T** (2006). p53 family members in myogenic differentiation and rhabdomyosarcoma development. **Cancer Cell** 10, 281-93. doi: 10.1016/j.ccr.2006.08.024 (IF 38.59)

Stiewe T, Pützer BM (2000). Role of the p53-homologue p73 in E2F1-induced apoptosis. **Nat Genet** 26, 464-9. doi: 10.1038/82617 (IF 41.38)